Share This Page
Drug Price Trends for NDC 58151-0083
✉ Email this page to a colleague
Average Pharmacy Cost for 58151-0083
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| CELEBREX 100 MG CAPSULE | 58151-0083-05 | 9.54970 | EACH | 2025-11-19 |
| CELEBREX 100 MG CAPSULE | 58151-0083-32 | 9.54970 | EACH | 2025-11-19 |
| CELEBREX 100 MG CAPSULE | 58151-0083-01 | 9.54970 | EACH | 2025-11-19 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 58151-0083
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 58151-0083
Introduction
The drug identified by NDC 58151-0083 corresponds to [Insert Drug Name], a pharmaceutical product approved for [Specify indication, e.g., oncology, cardiology, infectious diseases]. As an integral component of its therapeutic class, understanding its market dynamics, competitive landscape, pricing trends, and future projections is vital for stakeholders—including manufacturers, healthcare providers, investors, and policymakers.
This analysis offers a comprehensive overview of the current market environment, historical price developments, and forecasted trajectories, grounded in recent data and industry insight.
Product Overview
[Insert Drug Name] has garnered attention due to its [unique mechanism of action, therapeutic benefits, or recent clinical data]. It is marketed primarily for [indication], with added approvals or off-label use expanding its application scope.
- Market approval date: [Month, Year]
- Formulations: [e.g., injectable, oral, topical]
- Key manufacturers: [List of relevant companies]
- Therapeutic class: [e.g., monoclonal antibody, kinase inhibitor, antivirals]
Patient demographic trends, prevalence of the target condition, and reimbursement policy decisions notably influence its market trajectory.
Market Landscape
Current Market Size and Trends
Market size estimates for [Drug Name] suggest revenues of approximately $X billion in the United States alone (2022), driven by [factors such as increasing disease prevalence, expanded indications, or label extensions]. Globally, the market exceeds $Y billion, with Asia-Pacific emerging as a significant growth region due to [factors like improved healthcare infrastructure or expanded access].
Key drivers include:
- Growing disease prevalence: The prevalence of [indication] has increased at a compound annual growth rate (CAGR) of Z% over the past five years.
- Regulatory milestones: Recent approvals for additional indications or formulations, such as [list approvals], have expanded market potential.
- Reimbursement policies: Favorable payer coverage and high reimbursement levels bolster sales volumes.
Competitive Analysis
The market features a mix of branded [Drug Name] and biosimilars or generics, depending on patent status. Major competitors include [list of competitors], which offer similar or alternative therapies.
- Market share distribution: The leading brand accounts for approximately X%, with biosimilars capturing Y% of the market.
- Pricing strategies: Premium positioning due to clinical advantages or brand recognition sustains higher price points amid competitive pressures.
- Pipeline products: Upcoming competitors or next-generation formulations aim to challenge current market leaders.
Reimbursement and Policy Environment
Insurance coverage and reimbursement policies significantly influence pricing. In the U.S., [agency or payer] policies favor [specific reimbursement models or prior authorization trends], impacting access and sales volume. Internationally, regulatory environments and healthcare system reimbursement models vary, affecting regional pricing strategies.
Pricing Trends and Historical Data
List Price Evolution
Since its launch, [Drug Name] has experienced a dynamic pricing trajectory:
- Launch price: Approximately $X per [dose/unit] in [Year].
- Recent prices: Currently listed at $Y per [dose/unit], reflecting industry-standard inflation, manufacturing costs, and market positioning.
Factors Influencing Price Changes
- Patent protection: Extended patent life delays generic entry, maintaining higher prices.
- Market exclusivity periods: Data exclusivity and patent litigations influence pricing planning.
- Clinical value propositions: Demonstrated superiority in efficacy or safety can justify premium pricing.
- Market competition: Entry of biosimilars or generics typically reduces prices over time.
Price Projections
Based on recent market trends and external factors, projections suggest:
| Year | Estimated Average Price per Dose/Unit | Notes |
|---|---|---|
| 2023 | $Y | Current market, potential inflation adjustment. |
| 2024 | $Y + 3-5% | Anticipated inflation, demand growth. |
| 2025 | $Y + 5-8% | Possible new formulation launches or indication expansion. |
| 2030 | $Z | Patent expiration impact, increased biosimilar competition. |
In the absence of patent challenges, premium pricing is expected to sustain, but competitive pressures could lead to moderated price growth post-2025.
Forecast Analysis and Future Outlook
Near-term Outlook (2023-2025)
The initial years will likely maintain stable high prices due to patent protection, clinical differentiation, and limited biosimilar competition. Revenue growth hinges on:
- Market penetration in existing and new regions.
- Patient access programs and insurance reimbursement strategies.
- Regulatory approvals for expanding indications.
Medium to Long-term Outlook (2026-2030)
As patent exclusivity wanes:
- Generic and biosimilar entry will supply more cost-effective alternatives, exerting downward pressure.
- Pricing is projected to decline by 15-25% over five years post-patent expiry, aligned with typical biosimilar introduction trends.
- Market share shifts may favor cheaper alternatives, though brand loyalty and clinical differentiation could help preserve a significant segment.
Emerging therapies, such as [next-generation drugs or novel approaches], threaten to displace [Drug Name], potentially accelerating price erosion.
Strategic Recommendations
Stakeholders should consider:
- Investing in clinical differentiation to prolong exclusivity benefits.
- Engaging in early biosimilar development to capture market share post-patent expiry.
- Optimizing reimbursement negotiations to sustain pricing power.
- Monitoring regulatory developments that could influence market entry timing and pricing strategies.
Key Takeaways
- Market stability is expected in the short term due to patent protections and clinical differentiation.
- Pricing is projected to slowly decline post-2025, especially after patent expiration as biosimilars enter the market.
- Competitive landscape is intensifying, with biosimilar and generic pipeline products poised to reshape pricing dynamics.
- Emerging therapies and regulatory changes will heavily influence long-term market and price trajectories.
- Proactive strategies around clinical differentiation, biosimilar development, and payer negotiations are essential to maximize market positioning.
Conclusion
The value landscape for [Drug Name] remains robust in the near term, supported by patent exclusivity, clinical benefits, and strategic market positioning. However, impending patent expiries and evolving competition necessitate vigilant monitoring and adaptive strategies. Stakeholders should prepare for a phased price reduction, leveraging innovation, clinical differentiation, and strategic collaborations to sustain profitability.
FAQs
1. When is the patent for NDC 58151-0083 expected to expire?
Patent expiration is projected for [Year], after which biosimilar or generic entrants are anticipated, significantly impacting pricing.
2. How does competition from biosimilars affect the current pricing of this drug?
Biosimilar entry typically results in a 15-25% reduction in list prices within 3-5 years post-launch, driven by market competition and payer preference for cost savings.
3. What factors most influence the drug’s future market share?
Clinical efficacy, safety profile, price competitiveness, regulatory approvals for new indications, and payer reimbursement policies are key determinants.
4. Are there ongoing pipeline products that could disrupt the market?
Yes, several next-generation therapies in clinical or preclinical development could offer improved efficacy, safety, or convenience, challenging [Drug Name]'s market dominance.
5. How should healthcare payers approach reimbursement for this drug amid impending competition?
Payers should leverage cost-effectiveness data, negotiate value-based contracts, and consider biosimilar alternatives to optimize expenditures without compromising patient outcomes.
References
- [Insert precise references to industry reports, FDA/EMA approval documents, market research databases, and recent publications relevant to NDC 58151-0083]
More… ↓
